title: Protective effects of baicalin on LPS-induced injury in intestinal epithelial cells and intercellular tight junctions.
abstract: OBJECTIVE
  To investigate the protective effects and mechanisms of baicalin on lipopolysaccharide (LPS)-induced injury in intestinal epithelial cells and intercellular tight junctions.
  
  
  METHODS
  IEC-6 cells were stimulated with LPS (1.0 μg/mL), with or without baicalin, for 24 h. The levels of the inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-α were determined using ELISA. Quantitative real-time PCR was used for determining the mRNA expression level of claudin-3, occludin, and ZO-1; Western blot and immunofluorescence analysis were used for analyzing the expression level and the distribution patterns of ZO-1 protein.
  
  
  RESULTS
  Pretreatment with baicalin (10.0 μg/mL) improved LPS-stimulated cell viability and repressed IL-6 and TNF-α levels. In addition, pretreatment with baicalin up-regulated mRNA and protein expression levels of ZO-1 and kept the protein intact in IEC-6 cells injured with LPS.
  
  
  CONCLUSIONS
  Baicalin has the capacity to protect IEC-6 cells and the intercellular tight junctions from LPS-induced injury. The mechanisms may be associated with inhibiting the production of inflammatory cytokines, and up-regulating the mRNA and protein expression of ZO-1.
authors: School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
authors: Jian
authors: J
authors: Chen
authors: Ren
authors: R
authors: Zhang
authors: Jian
authors: J
authors: Wang
authors: Peng
authors: P
authors: Yu
authors: Quan
authors: Q
authors: Liu
authors: Dan
authors: D
authors: Zeng
authors: Houpan
authors: H
authors: Song
authors: Zaoyuan
authors: Z
authors: Kuang
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D062465:Claudin-3 / Q000235:genetics / Q000378:metabolism; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000378:metabolism; D004751:Enteritis / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D005419:Flavonoids / Q000494:pharmacology*; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000633:toxicity; D062793:Occludin / Q000235:genetics / Q000378:metabolism; D055550:Protein Stability / Q000187:drug effects; D021381:Protein Transport / Q000187:drug effects; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D019108:Tight Junctions / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D062826:Zonula Occludens-1 Protein / Q000819:agonists* / Q000235:genetics / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D062465:Claudin-3; C568124:Cldn3 protein, rat; D016207:Cytokines; D005419:Flavonoids; D005765:Gastrointestinal Agents; D008070:Lipopolysaccharides; D062793:Occludin; C568987:Ocln protein, rat; D012333:RNA, Messenger; C569044:Tjp1 protein, rat; D062826:Zonula Occludens-1 Protein; C482199:lipopolysaccharide, E coli O55-B5; C038044:baicalin
keywords: IEC-6 cells; ZO-1; anti-inflammation; cellules IEC-6; cytokine inflammatoire; inflammatory cytokine; occludin; occludine